Tue, Oct 21, 2014, 2:08 AM EDT - U.S. Markets open in 7 hrs 22 mins


% | $
Quotes you view appear here for quick access.

Rocky Mountain Chocolate Factory Inc. Message Board

gswkool 61 posts  |  Last Activity: 3 hours ago Member since: Jan 2, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • most likely the people who sold after viewing the first set of photos are reconsidering and buying back in after viewing the second set of photos released which shows much more improvement.....small stock, small market cap, .....it doesn't take much........IMO .... I'm currently long RXII, -it's a gamble but very cheaply priced...

  • gswkool gswkool Oct 16, 2014 10:09 PM Flag

    That is true- forgot about that. From what I can research, the fuel surcharge varies depending on price of fuel and type of shipment, and adjustments lag by a few months. A rapid decline in price will mean more $ for UPS, - but you're right - $750M savings is high since the company is already passing on fuel costs to customer...I wouldn't know how to put a number on it....low fule prices still a positive though...

  • gswkool gswkool Oct 16, 2014 10:52 AM Flag

    no, i don't believe that's correct. roughly, ups operating revenue was 46.5billion in 2013. Fuel costs account for 5.6% of operating revenue. that works out to 2.6billion. a savings of, say, 30%, would be an additional 780milion in profits. they earned roughly 4.3 billion in 2013. so a 30% fuel savings would boost net income by 18%. UPS goes to great lenghs in all aspects of its business to minimize fuel costs -

  • any company that can quickly develop and produce a vaccine. looks like you get to go straight to testing on humans - you don't have to go through years of pre-clinical & phase this and phase that -i don't know that nvax is working on anything for ebola, but given their past claims of how quickly they can develop and produce vaccines for masses, -hopefully they are working on something. I wonder if they would even be getting some prodding from our gov't {not in isolation -i would guess that the gov't is prodding others as well}...

  • would rather be holding CERS shares than many others that are in free fall......

  • I would guess that UPS uses hedging so they may not initially benefit as significantly as they could from the drop - however as you go out several months cheap profitability should help boost profitability. Just gotta keep an eye on Ebola and it's gonna be flu season again {bird flu scare} - they say once a century we are due for a pandemic ....................

  • Reply to

    For 18 patients Safe and some vision improvements.

    by eoinmnm Oct 15, 2014 10:40 AM
    gswkool gswkool Oct 15, 2014 11:04 AM Flag

    trial cost $$$ , dilution is preferable to a sellout by mgmt and giving up significant % of profits. Just look at NVAX. They are going it alone for their RSV vacccine candidate. They raised significant amount of money and stock is trading up post dilution. It all comes down to math and amount of confidence they have in success. Going it alone is sign of high confidence in the science. I'm a stockholder in NVAX and ACTC. Lets see how this one play out.....GLTA

  • It "may" not deliver less........boy, how people react to things of little substance...

  • gswkool by gswkool Oct 15, 2014 10:42 AM Flag

    CERS mentioned alongside others as an Ebola play......I would rather own CERS shares right now than the many others that are crumbling......

  • Reply to

    Newly In

    by flexed1962 Oct 14, 2014 3:49 PM
    gswkool gswkool Oct 14, 2014 6:30 PM Flag

    not bad prices - esp.in this market it's best to dollar cost average as the market is very shaky and has not yet capitulated - always smart to keep some $ on sidelines ...good luck with your investment...

  • gswkool by gswkool Oct 14, 2014 11:17 AM Flag

    less than thrilling earnings report. they tout 33 years of experience with their mgmt yet market cap is only 74M. Still, they pay a nice divi. I just don't see them as a growth company any more. Expect more thrashing -opening and closing of stores - with no real progress in expansion and profits. I had hopes when I originally purchased shares. They need to sell company or replace their upper mgt including their ceo ...imo.....

  • Reply to

    RNAi drugs are amazing future....

    by dragan7777777777 Oct 13, 2014 1:06 PM
    gswkool gswkool Oct 14, 2014 11:08 AM Flag

    you got that right! I just hope it doesn't get bought out before it is able to reach its peak value. This company can easily be another Celgene or Gilead, -it will just take some time. They've been getting blowout results when they do report clinical results. I would like to see more rapid development of a deeper pipeline, though.....look at ISIS pharma - I also own shares in ISIS pharma -they have quite a pipeline....

  • Reply to

    Good AVP-923 Phase II results. GO AVNR!

    by bkinwong Oct 13, 2014 6:35 PM
    gswkool gswkool Oct 13, 2014 7:38 PM Flag

    was it given to the patients or the caregivers? did they test to see what the caregivers were on when they provided their feedback to the patients? prhaps they should conduct another phase III trial with both patients and caregivers on AVP-923 - Personally, I'd prefer Johnny Walker......

  • Reply to

    My 2 Cents

    by bduchnowski Oct 11, 2014 3:42 PM
    gswkool gswkool Oct 13, 2014 3:38 PM Flag

    The stock is not acting like i would have expected it to - I was sure it would go up with the fda approval -so I don't know what is or is not priced in at this point - it is all but a done deal with ALIM having access to the money - so the market technically should have mostly priced it in - so i would expect no more than a small bump up - and i will most likely be wrong again when it pops...... one thing i feel good about is with two years of cash there should hopefully be some other form of good news coming over that timeframe.... I am still positive on the stock and to me it is undervalued at this point in time....

  • gswkool gswkool Oct 13, 2014 2:54 PM Flag

    I own both -but have a much larger stake in ALNY as I invested more and its more than tripled since purchase. I'm not sure what I expect from RXII at this point - the market is basically saying it has little to no value. If RXII science were recognized and had respect of the scientific community, then why such a tiny market cap? They seem to have qualified people on board. So I don't get it. I'm missing something and I guess I will find out what it is when the stock finally lands a big partner or it fails miserably.....GLTA

  • Reply to

    My 2 Cents

    by bduchnowski Oct 11, 2014 3:42 PM
    gswkool gswkool Oct 12, 2014 12:15 PM Flag

    I agree with your prognosis. The $25M was a big deal as they have enough cash to last to 2017. That's a long time. That doesn't include "potential" royalties on Lluvien and money from other licensing deals. So if you are a stockholder like me and have a long term view, the fall in share price could be an opportunity. It's a bad market - not a bad stock, that is driving the price down. The concerns that I do have are potential competition from new drugs for same conditions PSDV is going after. Stem cell treatment, RNA, and other platforms could encroach on PSDV's turf. I do have investments there as well, trying to cover enough bases -but it is hard to know who the winners will be. For me, I am watching Tethadur progress. That is key for me. When it goes from pre-clinical to the clinic, -that is the next milestone for me to invest more $$$. Not before. Other stuff I'm just tuning out.....

  • Reply to

    earnings report 10/14

    by gemini_dealer Oct 7, 2014 12:45 PM
    gswkool gswkool Oct 12, 2014 11:50 AM Flag

    stock is actually holding up well and we continue to pull in the nice dividend. when the world is in chaos -war, disease, global gloom - you can always go out and treat yourself to a yogurt or a piece of chocolate...i expect decent #s for this quarterly report....

  • gswkool gswkool Oct 9, 2014 5:48 PM Flag

    The problem is dilution. With such a low share price, and in a bad market, -raising money will become more difficult and expensive. Clinical trials cost $$$. The bigger trials cost bigger $$$. A small company like this will run smaller trials and try to get results sufficient enough to entice a big partner. It's an interesting mating dance. If they run out of cash before they are able to mate, they will go bust. The earlier in clinical testing that a deal is struck, usually the lousier the terms for the small fry. The company has $10M in cash, - it will need to raise more money sometime next year. I hope the market bounces back from all the carnage, but we are only a little off our highs. Plenty of room for markets to fall. I'm not making any additional purchases of any stocks until things stabilize. ......GLTA

  • Reply to

    Reason to sell?

    by bi0technician Oct 2, 2014 1:17 PM
    gswkool gswkool Oct 2, 2014 8:02 PM Flag

    I am a shareholder, but I am concerned with the price of the stock and the value the market is giving the company. I hold a bunch of biotechs to reduce risk. When I buy, I consider the potential relative to the price. I'm not a scientist, but I do read up on the science. And because I'm not a scientist, I also place weight on pedigree of the key personnel. "Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, RXi’s first RNAi product candidate, RXI-109, entered into RXi’s first human clinical trial in 2012." A Nobel Laureate seems qualified to me. Am I missing something?

  • gswkool gswkool Sep 29, 2014 9:41 PM Flag

    I'm a shareholder and bullish on PSDV, but I don't think they will get bought out. They are hard to put a value on at this stage. Tethadur is pre-clinical and that is their biggest opportunity. ALIM on the other hand is easier to quantify, as they only have Lluvien. I wouldn't be surprised if they get bought out - from a company with a sales force already in place who can sell Lluvien alongside their other products. They could save on administrative overhead as well as they would already have those personnel in place. Buyout of ALIM by right company would be beneficial for PSDV. that's my view anyway..

12.08-0.17(-1.39%)Oct 20 3:52 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.